They also developed a 71-gene expression signature, named the BRAF-RAS Score (BRS), designed to quantify the gene expression profile of a given tumor that resembles either the BRAF V600E or RAS-mutant profiles, the most common mutations found in PTC. This evidence concerns the gene BRAF and neoplasm.